Rapport Therapeutics Insider Purchase: 3,500 Shares Reported by Director

Rhea-AI Filing Summary

Wendy B. Young, a director of Rapport Therapeutics, Inc. (RAPP), reported a purchase of 3,500 shares of the company's common stock on 09/11/2025 at a reported price of $22.60 per share. After this transaction she beneficially owns 9,500 shares. The Form 4 filing was signed by an attorney-in-fact on 09/11/2025.

Positive

• Director purchase of 3,500 shares indicates insider accumulation
• Clear disclosure of transaction date, price, and post-transaction ownership (9,500 shares)

Negative

• None.

Insights

Securities Analyst

TL;DR: Director purchased 3,500 RAPP shares, raising beneficial holdings to 9,500 shares; transaction appears routine insider buying.

The filing documents a non-derivative acquisition by a reporting director on 09/11/2025: 3,500 common shares were acquired at $22.60 each, increasing beneficial ownership to 9,500 shares. The Form 4 is signed by an attorney-in-fact. The disclosure contains no additional context such as the source of funds or trading plan language.

Corporate Governance Expert

TL;DR: Disclosure meets Section 16 reporting requirements; transaction details are clear but contain no plan or arrangement language.

The Form 4 lists the reporter as a director and shows a straightforward purchase (code P) of 3,500 shares at $22.60 on 09/11/2025, leaving 9,500 shares beneficially owned. The filing is executed by an attorney-in-fact. There are no amendments, no derivatives, and no indication this was under a 10b5-1 plan in the provided text.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Wendy B.

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		P		3,500	A	$22.6	9,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Troy Ignelzi, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Wendy B. Young report on Form 4 for RAPP?

The Form 4 reports Wendy B. Young bought 3,500 common shares of RAPP on 09/11/2025 at $22.60 per share, resulting in 9,500 shares beneficially owned.

What was the transaction code and who signed the RAPP Form 4?

The transaction is recorded with code P (purchase). The filing was signed by Troy Ignelzi, Attorney-in-Fact on 09/11/2025.

Does the Form 4 show any derivative transactions for RAPP by the reporting person?

No. Table II for derivative securities contains no entries in the provided filing.

Is the reporting person an officer or director of Rapport Therapeutics (RAPP)?

Yes. The Form 4 indicates the reporting person, Wendy B. Young, is a Director of Rapport Therapeutics.